Dana CamAPS® FX - Advanced Therapeutics (UK) Ltd

Dana CamAPS® FX Overview

Dana CamAPS® FX was the first CE-Marked app-based hybrid closed loop algorithm and uses the Dana i insulin pump by Advanced Therapeutics (UK) Ltd. Hybrid Closed Loop Therapy is a form of Type 1 diabetes management, which merges continuous glucose monitoring with insulin delivery for real-time adjustments. Dana CamAPS® FX uses advanced learning algorithms to, over time, perfect insulin delivery for the individual, providing hands-off glucose management, automatically.

This hybrid closed loop system automatically adjusts insulin delivery based on your sensor glucose readings. Dana CamAPS® FX ensures adaptive and personalised insulin delivery, learning and adjusting according to your unique insulin needs while giving you the freedom to change settings as desired. This revolutionary technology runs seamlessly on your phone and is specifically designed for use with the Android™ OS.

‘The Best Algorithm Out There’

A game-changer for individuals of all ages living with Type 1 diabetes, Dana CamAPS® FX can be used by all ages and with a wide variety of insulins as the CamAPS® FX algorithm is licensed for use from ages 1 and up, in pregnancy and with ultra-rapid insulins. Developed at the prestigious University of Cambridge, it is widely regarded as ‘the best algorithm out there’. Rigorous randomised clinical trials have demonstrated substantial improvements in time spent in range, a reduction in HbA1c levels, as well as a decrease in time spent in both hypoglycaemia and hyperglycaemia, leading to an overall enhancement in well-being. With over 15 years of clinical studies to back up our claims, we can say with confidence that Dana CamAPS® FX could make a huge improvement to your life and how you manage your Type 1 diabetes. For comprehensive details, refer to our publications.

Providing Insulin Pump Therapy To More People Across The UK

Dana CamAPS® FX Vs Sensor Augmented Pump Therapy

The Tauschmann et al study ‘Closed-loop insulin delivery in suboptimally controlled Type 1 diabetes: a multicentre, 12-week randomised trial’ published in the Lancet 2018; 392: 1321–29 compares the use of the Dana CamAPS® FX hybrid closed loop system to sensor-augmented pump therapy.

It is crucial to emphasise that the comparative system is sensor-augmented pump therapy, rather than standard pump therapy. Research has established that insulin pump therapy with sensor augmentation already offers improved health benefits over standard insulin pump therapy, where glucose levels data is acquired through finger stick tests at specific intervals throughout the day.

During the 12-week trial period, subjects were randomly assigned either the Dana CamAPS® FX hybrid closed loop system or sensor-augmented pump therapy. The participants, aged six years and older, exhibited sub-optimally controlled glucose levels. The primary endpoint focused on the proportion of time with glucose concentration within the target range of 3·9–10·0 mmol/L at 12 weeks post-randomisation.

What Were The Results?

The closed-loop group demonstrated a significantly higher proportion of time with glucose concentration within the target range (65%, SD 8) compared to the control group (54%, SD 9).

Furthermore, HbA1c levels in the closed-loop group decreased from an initial value of 8·3% (SD 0·6) to 7·4% (SD 0·6) after the 12-week intervention period. In contrast, the control group’s HbA1c values were 8·2% (SD 0·5) at the beginning and 7·7% (SD 0·5) after intervention. The reductions in HbA1c percentages were notably greater in the closed-loop group compared to the control group.

Additionally, the time spent with glucose concentrations below 3·9 mmol/L (mean difference in change –0·83 percentage points, –1·40 to –0·16; p=0·0013) and above 10·0 mmol/L (mean difference in change 10·3 percentage points, –13·2 to –7·5; p<0·0001) was shorter in the closed-loop group than the control group.